News coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 THERAPEUTICS earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.7623803112881 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at 26.00 on Wednesday. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67. The stock has a 50 day moving average price of $16.75 and a 200-day moving average price of $16.90. The company’s market capitalization is $735.41 million.

G1 THERAPEUTICS (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.48). Analysts forecast that G1 THERAPEUTICS will post ($2.92) EPS for the current year.

GTHX has been the topic of several analyst reports. J P Morgan Chase & Co initiated coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “overweight” rating and a $23.00 price objective on the stock. Needham & Company LLC began coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They set a “buy” rating and a $34.00 price target on the stock. Wedbush assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Cowen and Company assumed coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They set an “outperform” rating and a $31.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: “G1 THERAPEUTICS (GTHX) Earning Somewhat Favorable Press Coverage, Study Shows” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/g1-therapeutics-gthx-earning-somewhat-favorable-press-coverage-study-shows/1557850.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with Analyst Ratings Network's FREE daily email newsletter.